IMCIVREE: Uses, Dosage & Side Effects

What Is IMCIVREE and What Is It Used For?

IMCIVREE contains the active substance setmelanotide, an eight-amino acid cyclic peptide that acts as a potent agonist of the melanocortin 4 receptor (MC4R). The melanocortin system is a critical neuroendocrine pathway in the hypothalamus that regulates energy balance, appetite, and body weight. Under normal physiological conditions, the leptin-melanocortin pathway operates as follows: adipose tissue secretes the hormone leptin in proportion to fat mass. Leptin signals to the hypothalamus, where it activates proopiomelanocortin (POMC) neurons. These neurons process POMC via the enzyme proprotein convertase subtilisin/kexin type 1 (PCSK1) to produce alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH then binds to and activates MC4R, which promotes satiety and reduces food intake while increasing energy expenditure.

In patients with genetic deficiency in any of the three critical components of this pathway — POMC, PCSK1, or the leptin receptor (LEPR) — the signaling cascade is disrupted. The result is insufficient MC4R activation, leading to severe, insatiable hunger (hyperphagia) and early-onset obesity that typically manifests in infancy or early childhood. These are extremely rare monogenic forms of obesity, with an estimated combined prevalence of fewer than 1 in 100,000 individuals. Affected patients develop severe obesity despite conventional interventions including dietary management, behavioral therapy, and exercise programs, because the fundamental biological drive for hunger is dysregulated at a molecular level.

Setmelanotide was designed to bypass these upstream deficiencies by directly activating MC4R, effectively restoring the satiety signal that is absent or diminished due to the genetic defect. By binding to MC4R with high affinity and potency, setmelanotide mimics the action of alpha-MSH, reducing hunger, promoting feelings of fullness after eating, and enabling patients to achieve meaningful weight loss for the first time. This mechanism of action is fundamentally different from other weight management medications, which typically work through different pathways (such as GLP-1 receptor agonism, lipase inhibition, or norepinephrine-serotonin modulation).

The efficacy of IMCIVREE was established in two pivotal Phase 3 clinical trials that enrolled patients with genetically confirmed POMC, PCSK1, or LEPR deficiency obesity:

• Study 1 (NCT02896192): This open-label trial enrolled 10 patients with POMC or PCSK1 deficiency obesity. After approximately one year of treatment with setmelanotide, 80% of patients achieved at least 10% body weight loss from baseline. The mean body weight reduction was approximately 25.6%. Patients also reported substantial reductions in hunger scores, with the most hunger-impaired individuals experiencing the greatest improvements. The reduction in hunger was evident within the first few weeks of treatment and was sustained throughout the study period.
• Study 2 (NCT03287960): This trial enrolled 11 patients with LEPR deficiency obesity. After approximately one year, 46% of patients achieved at least 10% body weight loss. The mean body weight reduction was approximately 12.5%. Hunger scores also improved significantly, demonstrating that setmelanotide was effective even in patients with a more distal defect in the melanocortin pathway (at the level of the leptin receptor rather than the POMC/PCSK1 processing level).

Both studies incorporated a randomized, double-blind withdrawal period in which patients who had been responding to setmelanotide were randomly assigned to continue active treatment or switch to placebo. During the withdrawal period, patients switched to placebo experienced rapid weight regain and return of hyperphagia, confirming that the weight loss and appetite-suppressing effects were directly attributable to setmelanotide treatment and not to placebo effect or natural disease course. Patients who resumed setmelanotide after the withdrawal period quickly regained the weight loss trajectory, further supporting the drug’s efficacy.

IMCIVREE was first approved by the U.S. Food and Drug Administration (FDA) in November 2020 for the treatment of obesity due to POMC, PCSK1, or LEPR deficiency in patients aged 6 years and older. The European Medicines Agency (EMA) granted conditional marketing authorization in July 2022. Subsequently, the FDA expanded the indication in 2022 to include obesity due to Bardet-Biedl syndrome (BBS), a related genetic condition characterized by obesity, retinal degeneration, polydactyly, and renal anomalies. IMCIVREE represents a paradigm shift in the treatment of monogenic obesity, providing the first targeted pharmacological therapy for patients whose obesity was previously intractable to all conventional interventions.

What Should You Know Before Taking IMCIVREE?

Contraindications

The primary contraindication to IMCIVREE use is known hypersensitivity (allergy) to setmelanotide or to any of the excipients in the formulation. The inactive ingredients in IMCIVREE include carboxymethylcellulose sodium, mannitol, phenol (as a preservative), edetate disodium dihydrate, and water for injections. Patients with known allergies to any of these components should not receive IMCIVREE.

IMCIVREE is also not indicated for patients without a confirmed genetic diagnosis of POMC, PCSK1, or LEPR deficiency. It should not be used for general obesity management, as its mechanism of action specifically targets the melanocortin pathway deficiency present in these rare genetic conditions. Using IMCIVREE in patients without these specific genetic defects would not be expected to produce the same therapeutic benefit and could expose patients to unnecessary risks.

Warnings and Precautions

Before starting IMCIVREE, discuss the following important safety considerations with your healthcare provider:

• Skin hyperpigmentation: Setmelanotide activates melanocortin 1 receptors (MC1R) in addition to MC4R. MC1R activation in melanocytes stimulates melanin production, which can cause generalized darkening of the skin (hyperpigmentation). This is an expected pharmacological effect of the drug and occurs in the majority of patients. In clinical trials, skin hyperpigmentation was reported in approximately 75% of patients. Darkening of pre-existing nevi (moles) and development of new nevi have also been observed. Patients should have a full-body skin examination before starting treatment and periodically during treatment to monitor for changes in existing moles or the appearance of new skin lesions. The hyperpigmentation is generally reversible upon discontinuation of IMCIVREE.
• Sexual adverse reactions: Melanocortin receptors are expressed in areas of the brain involved in sexual function. In clinical trials, spontaneous penile erections occurred in approximately 40% of male patients, and sexual adverse reactions (including unwanted sexual thoughts, genital sensations, and disturbances in sexual arousal) were reported in female patients. These effects are related to the pharmacological activity of the drug at central melanocortin receptors. Patients and caregivers (especially of pediatric patients) should be informed of these potential effects before starting treatment.
• Benzyl alcohol in neonates: Although IMCIVREE is not approved for patients under 6 years of age, the formulation contains phenol as a preservative. Healthcare providers should be aware of potential toxicity concerns with preservatives in pediatric populations.
• Disturbance in sexual development: Given the expression of melanocortin receptors in reproductive tissues, long-term effects on sexual development in pediatric patients have not been fully characterized. Pediatric patients should be monitored for appropriate pubertal development during treatment.

Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of IMCIVREE in pregnant women. In animal reproduction studies, subcutaneous administration of setmelanotide to pregnant rabbits during the period of organogenesis at doses approximately 10 times the maximum recommended human dose (based on body surface area) resulted in no adverse developmental effects. However, animal studies are not always predictive of human response. IMCIVREE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should discuss contraception with their healthcare provider before starting treatment.

It is not known whether setmelanotide is excreted in human breast milk. Due to the potential for serious adverse reactions in breastfed infants, including potential effects on skin pigmentation and sexual development, a decision should be made whether to discontinue breastfeeding or to discontinue IMCIVREE, taking into account the importance of the drug to the mother. Patients should consult their healthcare provider to make an informed decision about breastfeeding during IMCIVREE treatment.

Children and Adolescents

IMCIVREE is approved for use in pediatric patients aged 6 years and older with obesity due to POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. The safety and efficacy of IMCIVREE in pediatric patients younger than 6 years have not been established. In clinical trials, pediatric patients (aged 6 to 17 years) were enrolled and demonstrated efficacy responses consistent with adult patients, with both weight loss and hunger score improvements. Pediatric-specific considerations include age-appropriate dose titration schedules, monitoring of growth and development, surveillance for skin changes, and awareness of sexual adverse reactions in the context of pubertal development. Caregivers should be adequately informed about these potential effects and know how to administer the subcutaneous injection correctly.

Driving and Operating Machinery

No studies have been performed on the effects of IMCIVREE on the ability to drive and use machines. Based on the pharmacological properties and known adverse event profile, IMCIVREE is not expected to significantly impair the ability to drive or operate machinery. However, patients who experience dizziness, fatigue, or other central nervous system effects should exercise caution when driving or operating heavy machinery until they know how IMCIVREE affects them.

How Does IMCIVREE Interact with Other Drugs?

Setmelanotide is an eight-amino acid cyclic peptide that is metabolized primarily through proteolytic degradation, similar to other endogenous peptides. It is not a substrate, inhibitor, or inducer of cytochrome P450 (CYP) enzymes or major drug transporter proteins. As such, traditional pharmacokinetic drug-drug interactions mediated through CYP450 metabolism or transporter-based mechanisms are not expected to occur with IMCIVREE.

No formal drug interaction studies have been conducted with setmelanotide. In the clinical trial program, patients were permitted to use concomitant medications, and no clinically significant interactions were identified through population pharmacokinetic analyses. However, there are several pharmacological considerations that clinicians should be aware of when prescribing IMCIVREE alongside other medications:

The most clinically relevant pharmacological interaction consideration is with other melanocortin receptor agonists. Bremelanotide (approved for hypoactive sexual desire disorder in premenopausal women) and afamelanotide (approved for erythropoietic protoporphyria) also act on melanocortin receptors. Concurrent use of IMCIVREE with these agents could theoretically result in additive effects on melanocortin receptor activation, potentially increasing the risk of skin hyperpigmentation, cardiovascular effects, and sexual adverse reactions. Although no formal studies have evaluated these combinations, concurrent use is generally not recommended.

Patients taking antidepressant medications should be monitored carefully, given the independent risk of depression and suicidal ideation associated with IMCIVREE. While no pharmacokinetic interaction is expected between setmelanotide and antidepressants, the combination may have additive effects on mood, and close psychiatric monitoring is warranted. Patients should be counseled to report any worsening of mood, new-onset depressive symptoms, or suicidal thoughts immediately.

For patients with obesity-related comorbidities such as type 2 diabetes or hypertension, clinicians should anticipate that successful weight loss with IMCIVREE may necessitate dose adjustments of concurrent antidiabetic or antihypertensive medications. Regular monitoring of blood glucose and blood pressure is recommended, particularly during the initial months of treatment when weight loss may be most rapid.

What Is the Correct Dosage of IMCIVREE?

Adults (12 Years and Older)

IMCIVREE should be injected subcutaneously into the abdomen, thigh, or upper arm. The injection site should be rotated with each dose to reduce the risk of injection site reactions, lipodystrophy, and localized skin changes. Patients or caregivers should be trained by a healthcare professional on proper subcutaneous injection technique before self-administering the medication at home. The injection can be given at any time of day, but it is recommended to administer it at approximately the same time each day. IMCIVREE should be taken without regard to meals.

Before initiating treatment, healthcare providers should confirm the genetic diagnosis with documentation of pathogenic, likely pathogenic, or variants of uncertain significance in the POMC, PCSK1, or LEPR genes. The prescribing physician should also ensure that the patient understands the potential side effects, including skin hyperpigmentation, sexual adverse reactions, and the risk of depression and suicidal ideation.

Children (6 to 11 Years)

In pediatric patients, the dose is titrated more slowly than in adults, starting at 0.5 mg daily and increasing in increments every two weeks. The final maintenance dose may range from 1 mg to 3 mg daily, depending on the individual patient’s response to treatment and tolerability. Pediatric patients should be monitored regularly for growth, development, skin changes, and any adverse effects, including behavioral changes that could indicate depression or suicidal ideation.

Missed Dose

If a dose of IMCIVREE is missed, it should be administered as soon as remembered on the same day. If the missed dose is not remembered until the next day, patients should skip the missed dose and administer the next dose at the regular scheduled time. Two doses should not be taken on the same day to make up for a missed dose. Patients should be advised that occasionally missing a single dose is unlikely to significantly affect treatment outcomes, but consistent daily administration is important for maintaining the therapeutic effect. If multiple consecutive doses are missed, patients should contact their healthcare provider for guidance, as restarting treatment may require a brief dose re-titration period depending on the duration of interruption.

Overdose

There is limited clinical experience with overdose of IMCIVREE. In the event of an overdose, the patient should be monitored for signs and symptoms of adverse effects, particularly nausea, vomiting, diarrhea, facial flushing, and exaggerated sexual adverse reactions. Treatment of overdose should be supportive and symptomatic. There is no specific antidote for setmelanotide overdose. Due to the peptide nature of setmelanotide and its relatively short half-life (approximately 11 hours), symptoms of overdose are expected to be self-limiting. Healthcare providers should monitor vital signs, manage symptoms as clinically indicated, and provide supportive care as necessary.

Elderly Patients

Clinical studies of IMCIVREE did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. Given the extremely rare nature of the genetic conditions for which IMCIVREE is indicated (POMC, PCSK1, and LEPR deficiency), and the typical onset of severe obesity in infancy or early childhood, there is limited clinical experience with IMCIVREE in elderly populations. If used in older adults, dose selection should be cautious, starting at the lower end of the dosing range, and monitoring should account for the greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease in elderly patients.

What Are the Side Effects of IMCIVREE?

Like all medicines, IMCIVREE can cause side effects, although not everybody gets them. The safety profile of IMCIVREE has been characterized through clinical trials and post-marketing surveillance. Understanding the frequency and nature of potential adverse effects helps patients and healthcare providers make informed decisions about treatment and recognize important symptoms early.

The following side effects have been reported with IMCIVREE, organized by frequency category according to international standards:

Skin hyperpigmentation deserves special attention as it is the most distinctive side effect of IMCIVREE. It occurs because setmelanotide, while designed primarily to activate MC4R (which controls appetite), also activates MC1R in melanocytes (skin pigment cells). MC1R activation stimulates melanin production, resulting in generalized skin darkening. This effect was observed in approximately 75% of patients in clinical trials. The hyperpigmentation typically develops within the first few months of treatment and can affect the entire body, including the face, torso, and extremities. Darkening of pre-existing moles and development of new moles have also been reported. Importantly, this effect is generally reversible after discontinuation of IMCIVREE. Patients should undergo a full-body skin examination before starting treatment and at regular intervals during therapy to monitor for suspicious skin changes.

Sexual adverse reactions are another notable class of side effects related to the melanocortin pathway. MC4R and other melanocortin receptors are expressed in brain regions involved in sexual arousal and function. In clinical trials, spontaneous penile erections were reported in approximately 40% of male patients, including pediatric patients. In females, sexual adverse reactions including disturbances in sexual arousal and unwanted genital sensations were reported. These effects are pharmacologically expected and are related to the mechanism of action of the drug. Patients and caregivers (especially of pediatric patients) should be informed of these potential effects before treatment initiation. If sexual adverse reactions become distressing or persistent, dose reduction or treatment discontinuation should be considered.

Depression and suicidal ideation are the most serious potential side effects of IMCIVREE. Cases of depression and suicidal ideation have been reported during treatment, including in patients with no prior history of psychiatric illness. The mechanism underlying this risk is not fully understood but may be related to central melanocortin pathway modulation. The FDA prescribing information includes a warning about this risk and recommends monitoring all patients for new-onset or worsening depression, suicidal thoughts or behavior, and unusual changes in mood. Treatment should be discontinued if a patient develops suicidal thoughts or behavior.

How Should You Store IMCIVREE?

Proper storage of IMCIVREE is essential to maintain the stability and effectiveness of the medication. The following storage guidelines should be carefully followed:

• Before first use: Store IMCIVREE vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Keep the vials in the original carton to protect the solution from light. Do not freeze IMCIVREE. If the solution has been accidentally frozen, do not use it and contact your pharmacist for a replacement.
• After first use: Once the multi-dose vial has been punctured, it may be stored either in a refrigerator (2°C to 8°C) or at room temperature up to 25°C (77°F) for a maximum of 30 days. After 30 days from first puncture, any remaining solution should be discarded, even if the vial is not empty. Mark the date of first use on the vial label to help track the 30-day expiration period.
• General precautions: Keep IMCIVREE out of the reach and sight of children. Do not use IMCIVREE after the expiration date printed on the carton and vial label. The expiration date refers to the last day of that month. Before each injection, visually inspect the solution. IMCIVREE should be a clear, colorless to slightly yellow solution. Do not use the medication if it is cloudy, contains visible particles, or appears discolored.
• Disposal: Do not dispose of medications via household waste or wastewater. Used needles and syringes should be placed in a sharps disposal container immediately after use. Ask your pharmacist about local programs for medication and sharps disposal to help protect the environment.

Patients who travel should plan ahead to ensure proper storage conditions are maintained. IMCIVREE can be transported at room temperature (up to 25°C) for short periods, but prolonged exposure to elevated temperatures should be avoided. An insulated travel case may be useful for maintaining appropriate temperatures during travel. Patients should carry their medication in their hand luggage when flying, as cargo holds may expose the vial to freezing temperatures.

What Does IMCIVREE Contain?

Understanding the full composition of IMCIVREE is important for identifying potential allergens and ensuring safe administration. The detailed composition is as follows:

Active ingredient: Setmelanotide. Each multi-dose vial contains 10 mg of setmelanotide per milliliter of solution for injection. Setmelanotide is an eight-amino acid cyclic peptide with the amino acid sequence Ac-Arg-c[Cys-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2, where the two cysteine residues form a disulfide bridge that creates the cyclic structure. The molecular weight of setmelanotide acetate is approximately 1,117 daltons. The cyclic peptide structure is critical for its binding affinity and selectivity for melanocortin receptors.

Inactive ingredients (excipients):

• Carboxymethylcellulose sodium: A cellulose-derived polymer used as a viscosity-enhancing agent to ensure appropriate solution consistency for subcutaneous injection.
• Mannitol (E421): A sugar alcohol used as a tonicity agent to make the solution isotonic with body fluids, reducing pain and tissue irritation upon injection.
• Phenol: Used as an antimicrobial preservative in the multi-dose vial formulation. Phenol prevents microbial contamination during the 30-day in-use period after first vial puncture.
• Edetate disodium dihydrate (EDTA): A chelating agent that enhances the antimicrobial activity of phenol and helps maintain solution stability by binding trace metal ions.
• Hydrochloric acid and/or sodium hydroxide: Used to adjust the pH of the solution to the optimal range for stability and tolerability (approximately pH 6.0).
• Water for injections: Pharmaceutical-grade water used as the solvent for the formulation.

IMCIVREE is supplied as a clear, colorless to slightly yellow sterile solution in a multi-dose glass vial containing 1 mL of solution (10 mg of setmelanotide). The vial is sealed with a rubber stopper and aluminum crimp seal. Each vial is designed for multi-dose use with appropriate injection devices (syringes and needles, which are not included in the package and must be obtained separately). Patients should use a new sterile needle and syringe for each injection to prevent contamination and ensure accurate dosing.